The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 406.70
Bid: 406.60
Ask: 406.80
Change: -7.50 (-1.81%)
Spread: 0.20 (0.049%)
Open: 414.60
High: 415.20
Low: 406.00
Prev. Close: 414.20
RTO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

4 Mar 2021 07:05

RNS Number : 1024R
Rentokil Initial PLC
04 March 2021
 

4 March 2021

 

 

Directorate Changes including Appointment of Non-Executive Director

 

Rentokil Initial plc (FTSE: RTO, "the Company") today announces the appointment of Sarosh Mistry to its Board as a Non-Executive Director with effect from 1 April 2021. Sarosh will also become a member of the Remuneration Committee and the Nomination Committee from this date.

 

Sarosh has extensive experience as a senior executive, driving organic and inorganic growth in business-to-business services, especially in North America. He has deep experience of building businesses across the healthcare, retail, facilities management, hospitality, financial services and consumer technology industries, including innovation-led growth, service line extensions and new country entries (including emerging markets in Latin America and Asia). His executive experience has been in complex, geographically dispersed and multi-site businesses operating globally.

 

Sarosh is Chairman of Sodexo's North American services, which include clinical technology in health care settings, SaaS-based digital ecosystems, and food-focused delivery. He is also CEO of Sodexo's global Home Care Services business and a member of the listed group's executive committee. Prior to joining Sodexo in 2011, he worked in senior roles in major business-to-business and consumer organisations Compass, Starbucks, Aramark and Pepsico. Sarosh has a Bachelor's degree from St John's University, and a MBA from the A. Gary Anderson Graduate School of Management.

 

Commenting on the appointment Richard Solomons, Chairman, said:

 

"We are delighted to welcome Sarosh to the Board of Rentokil Initial. He has a track record of leading transformative growth and success in major support services businesses in our largest market, North America, as well as globally. We are confident that his experience and personal qualities will enable him to make a strong contribution to the Board." 

 

There are no further details to be disclosed relating to Sarosh Mistry under Section 9.6.13 of the Listing Rules.

 

Other Board Changes

 

Angela Seymour-Jackson, Non-Executive Director and Chair of the Remuneration Committee, has informed the Company that, having served on the Board for a period of 9 years, she does not intend to stand for re-election at the Company's AGM on 12 May 2021 and will, therefore, retire as a director of the Company from the conclusion of the meeting. The Company is pleased to announce that Cathy Turner, a Non-Executive Director and member of the Remuneration Committee since April 2020, will succeed Angela as Chair of the Remuneration Committee.

 

Commenting on the changes to Board, Richard Solomons, Chairman of Rentokil Initial, said: "I would like to thank Angela for her very significant contribution to the Board since she joined it in 2012, and for her work on the Remuneration Committee including as Chair since 2019. I'd also like to congratulate Cathy on her new appointment."

 

 

For further information please contact:

 

Rentokil Initial plc

 

Media

Malcolm Padley

07788 978199

Company Secretary

Daragh Fagan

07990 561702

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUPUCUWUPGPGW
Date   Source Headline
29th Apr 20243:00 pmRNSHolding(s) in Company
23rd Apr 20249:30 amRNSHolding(s) in Company
18th Apr 20247:00 amRNSQ1 Trading Update
2nd Apr 20241:28 pmRNSBlock listing Interim Review
2nd Apr 202412:17 pmRNSTotal Voting Rights
27th Mar 202410:23 amRNSAnnual Financial Report
19th Mar 20242:05 pmRNSAdditional Listing
14th Mar 202410:19 amRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSFinal Results
1st Dec 20237:00 amRNSNorth American Management Changes
10th Nov 20232:28 pmRNSDirector/PDMR Shareholding
3rd Nov 20234:26 pmRNSHolding(s) in Company
3rd Nov 20234:22 pmRNSDirector/PDMR Shareholding
1st Nov 202312:50 pmRNSHolding(s) in Company
31st Oct 202311:45 amRNSHolding(s) in Company
30th Oct 20233:03 pmRNSDirector/PDMR Shareholding
30th Oct 202311:55 amRNSCredit rating update
19th Oct 20237:00 amRNSQ3 Trading Update
2nd Oct 202311:35 amRNSBlock listing Interim Review
27th Sep 20232:35 pmRNSDirector/PDMR Shareholding
1st Aug 202312:42 pmRNSDirector/PDMR Shareholding
27th Jul 20237:00 amRNS2023 Interim Results
29th Jun 20239:00 amRNSNotice of Management Presentation
23rd Jun 20235:58 pmRNSDirector/PDMR Shareholding
19th May 20233:03 pmRNSDirector/PDMR Shareholding
12th May 20239:09 amRNSDirector/PDMR Shareholding
11th May 20239:17 amRNSResult of AGM
28th Apr 202310:55 amRNSHolding(s) in Company
21st Apr 20232:41 pmRNSDirector/PDMR Shareholding
20th Apr 20237:00 amRNSQ1 Trading Update
4th Apr 20239:37 amRNSAnnual Financial Report
3rd Apr 202310:08 amRNSBlock listing Interim Review
23rd Mar 20239:42 amRNSDirector/PDMR Shareholding
20th Mar 20234:47 pmRNSDirector/PDMR Shareholding
16th Mar 20237:05 amRNSDirectorate Change
16th Mar 20237:00 amRNSFinal Results
9th Mar 20239:23 amRNSDirector Declaration
27th Feb 20238:55 amRNSNotice of Management Presentation
9th Nov 20224:33 pmRNSDirector Declaration
1st Nov 20222:25 pmRNSCorrection: Q3 Trading Update
1st Nov 20227:00 amRNSQ3 Trading Update
31st Oct 20224:03 pmRNSTotal Voting Rights
24th Oct 20225:15 pmRNSHolding(s) in Company
21st Oct 20224:42 pmRNSHolding(s) in Company
20th Oct 202212:35 pmRNSHolding(s) in Company
19th Oct 202211:43 amRNSHolding(s) in Company
18th Oct 20225:22 pmRNSHolding(s) in Company
17th Oct 20226:07 pmRNSHolding(s) in Company
17th Oct 202211:51 amRNSHolding(s) in Company
14th Oct 20224:39 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.